Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Receivables (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Receivables for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 1478.31% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$114936.0 for FY2025, 61.59% up from the prior year.
  • Change in Receivables for Q4 2025 was $1.1 million at Neuphoria Therapeutics, up from -$10190.0 in the prior quarter.
  • The five-year high for Change in Receivables was $1.1 million in Q4 2025, with the low at -$80399.0 in Q4 2024.